|
1
|
Ross R: Atherosclerosis - an inflammatory
disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar
|
|
2
|
Suchindran S, Rivedal D, Guyton JR, et al:
Genome-wide association study of Lp-PLA(2) activity and mass in the
Framingham Heart Study. PLoS Genet. 6:e10009282010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Manrique C, Lastra G, Gardner M and Sowers
JR: The renin angiotensin aldosterone system in hypertension: roles
of insulin resistance and oxidative stress. Med Clin North Am.
93:569–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chait A, Han CY, Oram JF and Heinecke JW:
Thematic review series: the immune system and atherogenesis.
Lipoprotein-associated inflammatory proteins: markers or mediators
of cardiovascular disease? J Lipid Res. 46:389–403. 2005.
View Article : Google Scholar
|
|
5
|
Sudhir K: Clinical review:
lipoprotein-associated phospholipase A2, a novel
inflammatory biomarker and independent risk predictor for
cardiovascular disease. J Clin Endocrinol Metab. 90:3100–3105.
2005.PubMed/NCBI
|
|
6
|
Elkind MS, Tai W, Coates K, Paik MC and
Sacco RL: High-sensitivity C-reactive protein,
lipoprotein-associated phospholipase A2, and outcome after ischemic
stroke. Arch Intern Med. 166:2073–2080. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qi LH, Wang Y, Gao F, et al: Enhanced
stabilization of atherosclerotic plaques in apolipoprotein
E-knockout mice by combinatorial Toll-like receptor-1 and -2 gene
silencing. Hum Gene Ther. 20:739–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morris KV and Rossi JJ:
Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene
Ther. 13:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mäkinen PI, Koponen JK, Kärkkäinen AM, et
al: Stable RNA interference: comparison of U6 and H1 promoters in
endothelial cells and in mouse brain. J Gene Med. 8:433–441.
2006.PubMed/NCBI
|
|
10
|
Follenzi A and Naldini L: HIV-based
vectors. Preparation and use. Methods Mol Med. 69:259–274.
2002.PubMed/NCBI
|
|
11
|
Wang WY, Li J, Yang D, Xu W, Zha RP and
Wang YP: OxLDL stimulates lipoprotein-associated phospholipase
A2 expression in THP-1 monocytes via PI3K and p38 MAPK
pathways. Cardiovasc Res. 85:845–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
von der Thüsen JH, van Berkel TJ and
Biessen EA: Induction of rapid atherogenesis by perivascular
carotid collar placement in apolipoprotein E-deficient and
low-density lipoprotein receptor-deficient mice. Circulation.
103:1164–1170. 2001.PubMed/NCBI
|
|
13
|
von der Thüsen JH, van Vlijmen BJ, Hoeben
RC, et al: Induction of atherosclerotic plaque rupture in
apolipoprotein E−/− mice after adenovirus-mediated
transfer of p53. Circulation. 105:2064–2070. 2002.PubMed/NCBI
|
|
14
|
De Castro SH, Faria Neto HC and Gomes MB:
Platelet-activating factor acetylhydrolase (PAF-AH) activity in
patients with type 1 diabetes mellitus. Arq Bras Cardiol.
88:179–184. 2007.
|
|
15
|
Libby P: Changing concepts of
atherogenesis. J Intern Med. 247:349–358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miller RG, Costacou T and Orchard TJ:
Lipoprotein-associated phospho lipase A2, C-reactive
protein, and coronary artery disease in individuals with type 1
diabetes and macroalbuminuria. Diab Vasc Dis Res. 7:47–55.
2010.
|
|
17
|
Ballantyne CM, Hoogeveen RC, Bang H, et
al: Lipoprotein-associated phospholipase A2, high-sensitivity
C-reactive protein, and risk for incident coronary heart disease in
middle-aged men and women in the Atherosclerosis Risk in
Communities (ARIC) study. Circulation. 109:837–842. 2004.
View Article : Google Scholar
|
|
18
|
Mäkinen PI, Lappalainen JP, Heinonen SE,
et al: Silencing of either SR-A or CD36 reduces atherosclerosis in
hyperlipidaemic mice and reveals reciprocal upregulation of these
receptors. Cardiovasc Res. 88:530–538. 2010.PubMed/NCBI
|
|
19
|
Persson M, Nilsson JA, Nelson JJ, Hedblad
B and Berglund G: The epidemiology of Lp-PLA(2): distribution and
correlation with cardiovascular risk factors in a population-based
cohort. Atherosclerosis. 190:388–396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koenig W and Khuseyinova N:
Lipoprotein-associated and secretory phospholipase A2 in
cardiovascular disease: the epidemiological evidence. Cardiovasc
Drugs Ther. 23:85–92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wilensky RL, Shi Y, Mohler ER III, et al:
Inhibition of lipoprotein-associated phospholipase A2
reduces complex coronary atherosclerotic plaque development. Nat
Med. 14:1059–1066. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu MM, Zhang J, Wang WY, et al: The
inhibition of lipoprotein-associated phospholipase A2
exerts benefcial effects against atherosclerosis in LDLR-defcient
mice. Acta Pharmacol Sin. 32:1253–1258. 2011.PubMed/NCBI
|
|
23
|
Serruys PW, García-García HM, Buszman P,
et al: Effects of the direct lipoprotein-associated phospholipase
A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Circulation. 118:1172–1182. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu J, Chen R, Marathe GK, Febbraio M, Zou
W and McIntyre TM: Circulating platelet-activating factor is
primarily cleared by transport, not intravascular hydrolysis by
lipoprotein-associated phospholipase A2/PAF acetylhydrolase. Circ
Res. 108:469–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tellis CC and Tselepis AD: The role of
lipoprotein-associated phospholipase A2 in
atherosclerosis may depend on its lipoprotein carrier in plasma.
Biochim Biophys Acta. 1791:327–338. 2009.PubMed/NCBI
|
|
26
|
Singh U, Zhong S, Xiong M, Li TB,
Sniderman A and Teng BB: Increased plasma non-esterified fatty
acids and platelet-activating factor acetylhydrolase are associated
with susceptibility to atherosclerosis in mice. Clin Sci.
106:421–432. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuniyasu A, Tokunaga M, Yamamoto T, et al:
Oxidized LDL and lysophosphatidylcholine stimulate plasminogen
activator inhibitor-1 expression through reactive oxygen species
generation and ERK1/2 activation in 3T3-L1 adipocytes. Biochim
Biophys Acta. 1811:153–162. 2011. View Article : Google Scholar
|
|
28
|
Tsironis LD, Katsouras CS, Lourida ES, et
al: Reduced PAF-acetylhydrolase activity associated with Lp(a) in
patients with coronary artery disease. Atherosclerosis.
177:193–201. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Quarck R, De Geest B, Stengel D, et al:
Adenovirus-mediated gene transfer of human platelet-activating
factor-acetylhydrolase prevents injury-induced neointima formation
and reduces spontaneous atherosclerosis in apolipoprotein
E-deficient mice. Circulation. 103:2495–2500. 2001. View Article : Google Scholar
|
|
30
|
Karasawa K: Clinical aspects of plasma
platelet-activating factor acetylhydrolase. Biochim Biophys Acta.
1761:1359–1372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karasawa K, Harada A, Satoh N, Inoue K and
Setaka M: Plasma platelet activating factor-acetylhydrolase
(PAF-AH). Prog Lipid Res. 42:93–114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Naoki K, Asano K, Satoh N, et al: PAF
responsiveness in Japanese subjects with plasma PAF acetylhydrolase
deficiency. Biochem Biophys Res Commun. 317:205–210. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mohler ER III, Ballantyne CM, Davidson MH,
et al: The effect of darapladib on plasma lipoprotein-associated
phospholipase A2 activity and cardiovascular biomarkers
in patients with stable coronary heart disease or coronary heart
disease risk equivalent: the results of a multicenter, randomized,
double-blind, placebo-controlled study. J Am Coll Cardiol.
51:1632–1641. 2008.PubMed/NCBI
|
|
34
|
Opal S, Laterre PF, Abraham E, et al:
Recombinant human platelet-activating factor acetylhydrolase for
treatment of severe sepsis: results of a phase III, multicenter,
randomized, double-blind, placebo-controlled, clinical trial. Crit
Care Med. 32:332–341. 2004. View Article : Google Scholar
|
|
35
|
Henig NR, Aitken ML, Liu MC, Yu AS and
Henderson WR Jr: Effect of recombinant human platelet-activating
factor-acetylhydrolase on allergen-induced asthmatic responses. Am
J Respir Crit Care Med. 162:523–527. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lavi S, McConnell JP, Rihal CS, et al:
Local production of lipoprotein-associated phospholipase
A2 and lysophosphatidylcholine in the coronary
circulation: association with early coronary atherosclerosis and
endothelial dysfunction in humans. Circulation. 115:2715–2721.
2007.PubMed/NCBI
|
|
37
|
Laxton RC, Hu Y, Duchene J, et al: A role
of matrix metalloproteinase-8 in atherosclerosis. Circ Res.
105:921–929. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Didion SP, Kinzenbaw DA, Schrader LI, Chu
Y and Faraci FM: Endogenous interleukin-10 inhibits angiotensin
II-induced vascular dysfunction. Hypertension. 54:619–624. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brasier AR, Recinos A III and Eledrisi MS:
Vascular inflammation and the renin-angiotensin system.
Arterioscler Thromb Vasc Biol. 22:1257–1266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yanai H, Tomono Y, Ito K, Furutani N,
Yoshida H and Tada N: The underlying mechanisms for development of
hypertension in the metabolic syndrome. Nutr J. 7:102008.
View Article : Google Scholar : PubMed/NCBI
|
